The PRS was associated with a higher risk of NASH in both crude and adjusted analysis (OR 3.59 per unit increase, 95% CI = 1.53–8.43; aOR 3.81 95% CI = 1.48–9.81); hence, this was largely driven by the PNPLA3 component. The gene discussed is PNPLA3; the disease is metabolic dysfunction-associated steatohepatitis.